作为HIF-1α抑制剂的PX-478会损害宫癌中MesoCAR T细胞的抗瘤功能
Ahmad Reza Panahi Meymandi1, Behnia Akbari1, Tahereh Soltantoyeh1
1Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Frontiers in oncology
|March 1, 2024
概括
低氧诱导因子-1α (HIF-1α) 途径在宫癌中显著影响CAR T细胞功能. 用PX-478抑制HIF-1α损害了CAR T细胞细胞毒性并诱导了疲劳,这表明瘤免疫力中具有复杂的作用.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
背景情况:
- 化学抗原受体 (CAR) T细胞疗法对血液癌症有希望,但与宫癌等固体瘤作斗争.
- 瘤缺氧,以高水平的缺氧诱导因子-1α (HIF-1α) 为特征,损害了CAR T细胞的疗效.
- 向HIF-1α是一种潜在的策略,可以增强低氧瘤中CAR T细胞治疗.
研究的目的:
- 在宫癌的背景下,研究HIF-1α抑制剂PX-478对CAR T细胞功能的影响.
- 分析宫癌患者的HIF-1α表达及其与预后的相关性.
- 评估PX-478对T细胞增殖,细胞因子产生,细胞毒性和耗尽标记物的影响.
主要方法:
- 进行了in-silico和in-vitro实验.
- 在宫癌患者数据中分析了HIF-1α表达.
- 评估了PX-478对T细胞和MesoCAR T细胞的影响,包括增殖,细胞因子释放,细胞毒性和疲劳标记.
主要成果:
- 宫癌患者的高HIF-1α表达与预后不佳相关.
- PX-478有效地降低了T细胞和HeLa细胞中的HIF-1α水平.
- PX-478抑制了非特异性T细胞增殖,但对抗原特异性CAR T细胞增殖的影响很小.
- PX-478显著降低了CAR T细胞细胞毒性,并增加了T细胞耗尽.
结论:
- HIF-1α通路对于CAR T细胞功能和缺氧瘤的命运至关重要.
- PX-478治疗会损害CAR T细胞的抗瘤活性,并诱导疲劳.
- 需要进一步的研究,以了解HIF-1α下游目标,以开发有效的抗低氧瘤组合疗法.
更多相关视频
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.0K
08:29Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
14.8K
相关概念视频
01:27Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K